Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

400.43 +4.11 (+1.04%)

Delayed Quote Updated: 4:00 PM EST, Nov 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Madrigal (MDGL) Q2 Revenue Soars 1,313% ↗

August 05, 2025

Via The Motley Fool

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Beats Q2 2025 Revenue Estimates and Narrows Losses on Strong Rezdiffra Sales ↗

August 05, 2025

Madrigal Pharmaceuticals (MDGL) beats Q2 2025 revenue estimates with $212.8M, driven by strong Rezdiffra sales, narrowing losses. Stock rises 12.8% pre-market.

Via Chartmill

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

European Advisory Panel Backs Conditional Approval For Madrigal's Fatty Liver Disease Drug ↗

June 20, 2025

Rezdiffra wins CHMP backing for conditional EU approval in MASH with fibrosis; decision from European Commission expected in August.

Via Benzinga

5 Health Care Stocks With Whale Alerts In Today's Session ↗

June 20, 2025

Via Benzinga

2 Monster Stocks in the Making to Buy Now and Hold for 10 Years ↗

May 13, 2025

Via The Motley Fool

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

Why Madrigal Pharmaceuticals Stock Is Soaring Today ↗

February 26, 2025

Via The Motley Fool

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

Why Madrigal Pharmaceuticals Stock Is Sinking Today ↗

January 13, 2025

Via The Motley Fool

Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock ↗

May 11, 2025

Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive trial results and the continued demand for its FDA-approved treatment,...

Via Stocktwits

Topics Death

Uncovering Potential: Madrigal Pharmaceuticals's Earnings Preview ↗

April 30, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

April 25, 2025

Via Benzinga

Workday, ACM Research, ZoomInfo Technologies, CEVA, Intuit And Other Big Stocks Moving Higher On Wednesday ↗

February 26, 2025

Via Benzinga

Earnings Preview For Madrigal Pharmaceuticals ↗

October 30, 2024

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

February 26, 2025

Via Benzinga

Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis ↗

February 26, 2025

Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and revenue expectations.

Via Benzinga

8 Health Care Stocks Whale Activity In Today's Session ↗

January 20, 2025

Via Benzinga

Why Madrigal Pharmaceuticals Stock Was Plummeting This Week ↗

January 17, 2025

Via The Motley Fool

Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

December 18, 2024

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

Via MarketBeat

Top 3 Health Care Stocks That May Dip This Month ↗

November 25, 2024

Via Benzinga

Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst ↗

November 25, 2024

Via The Motley Fool

3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move ↗

November 23, 2024

Via The Motley Fool

MDGL: A Promising Play In The Weight Loss Drug Space ↗

November 22, 2024

The launch of Madrigal Pharmaceuticals Inc.’s NASH drug Rezdiffra exceeded all expectations in the recent quarterly earnings release. The stock rose more than 50% in a few days – and the company now...

Via Talk Markets

Topics Stocks / Equities

1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More ↗

November 10, 2024

There's a bright future ahead for this company.

Via The Motley Fool

Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? ↗

November 03, 2024

Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%).

Via Benzinga

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH ↗

November 01, 2024

Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water.

Via Investor's Business Daily

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 31, 2024

Via Benzinga

Is Madrigal Pharmaceuticals Stock a Buy? ↗

August 17, 2024

The biotech could be worth a lot more in 10 years.

Via The Motley Fool

This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock ↗

August 14, 2024

One player's minor pain is another's moderate gain.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.